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Abstract
Tauopathies are characterized by abnormal aggregation of the microtubule associated protein tau.
This aggregation is thought to occur when tau undergoes shifts from its native conformation to one
that exposes hydrophobic areas on separate monomers, allowing contact and subsequent
association into oligomers and filaments. Molecular chaperones normally function by binding to
exposed hydrophobic stretches on proteins and assisting in their refolding. Chaperones of the heat
shock protein 70 (Hsp70) family have been implicated in the prevention of abnormal tau
aggregation in adult neurons. Tau exists as six alternatively spliced isoforms, and all six isoforms
appear capable of forming the pathological aggregates seen in Alzheimer's disease. Because tau
isoforms differ in primary sequence, we sought to determine whether Hsp70 would differentially
affect the aggregation and microtubule assembly characteristics of the various tau isoforms. We
found that Hsp70 inhibits tau aggregation directly, and not through inducer mediated effects. We
also determined that Hsp70 inhibits the aggregation of each individual tau isoform and was more
effective at inhibiting the three repeat isoforms. . Finally, all tau isoforms robustly induced
microtubule formation while in the presence of Hsp70. The results presented herein indicate that
Hsp70 affects tau isoform dysfunction while having very little impact on the normal function of
tau to mediate microtubule assembly. This indicates that targeting Hsp70 to tau may provide a
therapeutic approach for the treatment of tauopathies that avoids disruption of normal tau function.
The microtubule associated protein tau exists as six isoforms generated by alternative
splicing at exons 2, 3, and 10 (1, 2). Splicing of the amino-terminal exons 2 and 3 results in
isoforms possessing either zero (0N), one (1N) or two (2N) N-terminal inserts. Exon 10
encodes for one of four functional microtubule binding repeats (MTBRs) located near the
carboxyl-terminus. Alternative splicing at exon 10 results in isoforms possessing either 3 or
4 repeats (3R or 4R, respectively). Tauopathies are a class of neurodegenerative disorders
that arise from the misfolding of tau protein, resulting in its aggregation into amyloid fibrils
(reviewed in (3)). Changes in the alternative splicing of tau have been associated with
tauopathies such as progressive supranuclear palsy (PSP) and corticobasal degeneration
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(CBD), which have an increase in 4R tau. By contrast, Pick's disease generally has an
increase in 3R tau (reviewed in (4)). However, in Alzheimer's disease (AD), tau isoform
ratios are somewhat controversial with multiple reports of no differences in splicing between
AD and controls (5-10) and multiple reports of altered splicing ratios (11-16). These
differences in observations are likely due to the difficulty and technical limitations of the
experimental approaches employed. However, it is also likely that in addition to any
potential changes in altered isoform ratios, post-translational modifications of isoforms and
their interactions with other cellular proteins could play a major role in pathogenesis. We
have shown previously that tau isoform aggregation is affected by the buffer conditions, the
type of inducer for aggregation used, and post-translational modifications (17). The
aggregation differences caused by changes in the local environment indicate that each
isoform may have a distinct role in the aggregations process leading to neurodegeneration.
In neurodegenerative tauopathies, molecular chaperones such as the heat shock proteins are
believed to play a significant role in reducing the accumulation of abnormal tau (reviewed in
(18)). Molecular chaperones have multiple roles, including the prevention of inappropriate
aggregation of hydrophobic regions of misfolded proteins, targeting proteins to subcellular
compartments, and assisting in degradation of proteins (reviewed in (19)). In the central
nervous system, Hsp70 levels are normally low but expression of the protein is increased in
response to stresses such as hypoxia, elevated temperature, inflammation, and other insults
(reviewed in (20)). Hsp70 functions by binding exposed hydrophobic regions of proteins via
its substrate-binding domain while its ATPase domain hydrolyzes ATP to ADP, creating a
higher affinity interaction with the substrate (reviewed in (21)). Hsp70 can then directly
assist in protein refolding, transfer the protein to the heat shock protein 90 (Hsp90) system,
or transfer the protein to the chaperonin system for refolding (reviewed in (21)).
Elevated levels of stress response proteins have been observed in AD (reviewed in (18)),
leading to an increased focus on the role of chaperones in the disease state. Elevated protein
levels of Hsp70/90 have been observed in hippocampal sections from AD patients as
compared to aged matched controls (22-24). In specific hippocampal neurons there is an
inverse relationship of tau aggregation and Hsp70/90 levels (23). Moreover, in both animal
and cellular models, the expression of Hsp70 has been shown to reduce the levels of
abnormal tau (23, 25). The Hsp70 family member, heat shock cognate 70 protein (Hsc70),
has been shown to bind tau directly in vitro (26), and multiple studies have observed a tau/
Hsp70 interaction in vivo (23-27). Although the constitutively expressed Hsc70 is more
abundant and has been shown to be involved in tau processing in aging and
neurodegenerative diseases (28), we have chosen to focus this study on Hsp70 because of its
inverse relationship with tau pathology and its ability to reduce abnormal tau levels in
models of neurodegeneration. Likewise, although it is known that Hsp70 activity is greatly
enhanced by co-chaperones such as J-proteins and nucleotide exchange factors (NEFs) (29),
we have chosen to focus this initial study on the intrinsic ability of Hsp70 to influence tau
function in the absence of ATP cycling. Due to the large number of J-proteins and NEFs that
could play a role in modulating Hsp70 activity toward tau, these important questions will be
the focus of future research efforts.
Previous work studying Hsp70/tau interactions has shown Hsp70 reduces abnormal tau
aggregation (24, 30). However, tau exists as six isoforms that are known to have differing
propensities for microtubule-binding and aggregation (reviewed in (31-37)). Furthermore, it
is likely that the inclusion or exclusion of exons 2, 3 and 10 could alter the overall
conformation of tau, perhaps affecting the availability of the microtubule-binding repeats.
Lastly, it has been observed that the microtubule binding repeats are the major sites for
microtubule binding (38-40), tau aggregation (41, 42) and heat shock protein interactions
(26). Based on this evidence, we sought to determine whether Hsp70 would differentially
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affect the aggregation and microtubule assembly properties of the individual tau isoforms in
vitro.
In this study, we demonstrate that Hsp70 inhibits tau aggregation in vitro but has varying
effects on individual tau isoforms. Additionally, Hsp70 had differential, but minor effects on
the nucleation and stabilization of microtubules by the individual tau isoforms. These results
suggest that Hsp70 is effective in inhibiting the aggregation of all six isoforms of tau while
maintaining the ability of tau to stabilize microtubules, providing biochemical evidence that
the up-regulation of Hsp70 may afford protection against tau-induced neurodegeneration.
EXPERIMENTAL PROCEDURES
Protein purification
WT tau isoforms (2N4R, 2N3R, 1N4R, 1N3R, 0N4R, and 0N3R) cloned into a PT7c vector
with an N-terminal polyhistidine tag have been previously described (17, 26, 43). Hsp70
(HSPA1A) (Open Biosystems) was cloned into a pET28b vector (Novagen) with an N-
terminal polyhistidine tag. Proteins were expressed in E. coli and purified by nickel affinity
chromatography using Chelating Sepharose Fast Flow (GE Healthcare) followed by size
exclusion chromatography on a Superdex 200 column using an ÄKTA FPLC (GE
Healthcare) as previously described (17). Protein concentration was determined by a
commercially available BCA kit (Pierce), and the purity of each protein was assayed by
electrophoresis of microgram amounts on SDS-PAGE gels followed by staining with
Coomassie Brilliant Blue R-250.
Tau aggregation with Arachidonic Acid, Congo Red, and Heparin
Tau isoforms (2-4μM) in 10 mM Hepes pH 7.64, 100 mM NaCl, 0.1 mM EDTA and 5 mM
DTT were incubated with either arachidonic acid (ARA) or Congo red (CR) to induce
aggregation (17, 44-49). BSA (0.25 μM) was added to prevent aggregate clumping at higher
temperatures. There were no significant differences in the detected amount of
polymerization between tau aggregation reactions performed with or without BSA (data not
shown). All reactions were carried out at 37 °C for 18 hours. ARA (Cayman Chemicals;
90010.1) was diluted to a final concentration of 75-150 μM, and the concentration of ethanol
carrier was kept constant at 3.75%. Congo red (CR) (Sigma; C6277) was dissolved in water
and used at a final concentration of 10 μM in aggregation buffer (45, 50). Alternatively,
heparin (Sigma; H4784; estimated molecular weight between 6-30 kDa) was dissolved in
water and used at a final concentration of 6 μg/ml to induce 2N4R tau (2 μM) aggregation in
low salt buffer (30 mM Hepes pH 7.64, 18 mM NaCl and 5 mM DTT) (17, 44, 51). For
inhibition studies, Hsp70 (0-2 μM) was added to aggregation reactions containing ARA, CR
or heparin as described above. No differences were observed between his-tagged Hsp70 and
non-his-tagged Hsp70 (data not shown). Aggregation was assayed using right angle laser
light scattering (LLS), thioflavin S fluorescence (ThS), and transmission electron
microscopy (TEM) similar to that previously described (44) with the following changes: the
laser used for LLS was a 12 mW solid state 532 nm laser operating at 7.6 mW (B&W Tek)
and the electron microscope used was a Tecnai F20 XT Field Emission TEM (FEI). The
concentration of Hsp70 required to achieve 50% maximal inhibition was determined using
GraphPad Prism by plotting the percent aggregation (normalized to the largest and smallest
data points in each set) versus the log([Hsp70]) and fitting to an inhibitory dose response
curve with variable slope:
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Where X is the log of concentration of Hsp70 in μM, Y is the normalized response
(decreasing from 100% (no inhibition) to 0% (complete inhibition) with increasing Hsp70
concentrations), log(IC50) is in the same log units as Hsp70 concentration and is the Hsp70
concentration required to achieve 50% of its inhibitory effects, and HillSlope is the
steepness of curve from no inhibition to maximal inhibition.
Tau aggregation in the presence of ATP and Hsp70
4 μM 2N4R tau aggregation reactions with 150 μM ARA was performed as described
above. Hsp70 was included at a final concentration of 1 μM either with 500 μM ATP or with
500 μM ATPγS. Hsp70 without nucleotide added was performed as a control. Reactions
were incubated for 18 hrs at 37 °C and aggregation was measured by ThS fluorescence.
Differences between reactions were compared using a t-test.
Hsp70 disassembly of pre-formed tau aggregates
4 μM 2N4R tau aggregation reactions were performed in polymerization buffer with 0.25
μM BSA, 150 μM ARA at 37 °C. After 6 hrs incubation, Hsp70 was added to the reaction at
a final concentration of 1 μM without ATP or at a final concentration of 2 μM Hsp70 and 2
mM ATP. An equal volume of buffer was added to a control reaction to account for dilution
effects. The reactions were incubated for a further 18 hrs and the amount of aggregated
material was measured by TEM for aggregate lengths and analyzed as described below.
Aggregate length distribution analysis of transmission electron microscopy (TEM) images
TEM images were analyzed for aggregate lengths using previously published protocols (52),
with the exception that Image Pro Plus 6 (Media Cybernetics) was used for quantitation.
Images were set to a threshold that included electron dense aggregates, but any non-specific
background material or dense material that did not meet user defined criteria for length and
area were ignored. Control samples containing 2 μM Hsp70 in the absence of tau were used
to determine background levels of Hsp70 aggregation (53, 54). Only objects that were
longer than 25 nm, and having an area greater than 375 nm2 (25 nm long and 15 nm wide)
were included in the quantitative analysis, similar to previously published protocols for
quantitative electron microscopy of tau aggregates (55). The length of each aggregate from
five images per reaction were determined for each isoform at three different Hsp70
concentrations: 1) no Hsp70, 2) a concentration of Hsp70 close to the IC50, and 3) a
concentration of Hsp70 that resulted in maximal inhibition of tau aggregation. The resulting
aggregate lengths were transformed to a log scale and a frequency distribution was
performed using GraphPad Prism. The data was fit to a Gaussian equation and tested for
significant differences using a global fit comparison sum-of-squares F test.
Microtubule assembly
Microtubule assembly assays were performed using a commercially available DAPI
fluorescence based porcine tubulin polymerization assay kit (Cytoskeleton), according to the
manufacturer's protocol for detecting enhancers of tubulin assembly in the absence of
glycerol or paclitaxel (56, 57). Reactions were performed using 1 μM tubulin and 1 μM tau
either with or without 1 μM Hsp70. Reactions were incubated at 37 °C and readings were
taken every minute for one hour duration using a Molecular Devices Flexstation II plate
reader with an excitation wavelength of 355 nm and an emission wavelength of 460 nm.
Tubulin assembly reactions (without tau) containing 1 μM taxol alone, 1 μM Hsp70 alone
and tubulin alone were used as controls.
Data for microtubule assembly reactions were normalized to 1 μM taxol stabilized
microtubule reactions run in parallel to adjust for variability in tubulin assembly with the
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background reading set to a value of zero and the maximum amount of fluorescence
observed set to a value of 1. Reactions for isoforms with and without Hsp70 were always
performed at the same time and with the same aliquot of tubulin to ease comparisons.
Normalized data was fit to a Gompertz growth curve (58, 59) , defined as:
where Y is the relative fluorescence level, a is the maximum amount of fluorescence, x is
time, b is 1/kapp where kapp is proportional to the rate of assembly, and c is the point of
greatest increase in Y. Lag time to significant assembly (calculated by c-b), kapp and
maximum assembly (a) were determined from independent trials with or without Hsp70 and
are represented as the mean ± SD.
Fitting Hsp70 inhibition data to binding models
The inhibition curves of 3R tau aggregation by different concentrations of Hsp70 were fit by
a single site binding equation:
where ν is the fraction of tau bound by Hsp70, Bmax is maximal binding, K1 is the
association constant for binding and A is the amount of free Hsp70. The experimental
inhibition curves were fit manually by adjusting the values of Bmax and K1 assuming that
inhibition is directly proportional to binding of Hsp70.
The inhibition curves of 4R tau aggregation by different concentrations of Hsp70 were fit by
a two site binding equation:
where ν is the fraction of tau bound by Hsp70, Bmax is maximal binding, K1 is the
association constant for binding to the first site, K2 is the association constant for the second
site and A is the amount of free Hsp70. The values Bmax of K1 were kept the same as the fits
for 3R isoforms. The inhibition curves were fit manually by adjusting the values for K2
assuming that inhibition was directly proportional to the amount of tau with two Hsp70
bound (tau bound by a single Hsp70 would not be inhibited for 4R isoforms).
RESULTS
Hsp70 inhibits 2N4R tau aggregation directly
We sought to confirm that Hsp70 inhibits tau aggregation in vitro by using a variety of
aggregation inducers. The inducers arachidonic acid (ARA) (60), heparin (61), and Congo
red (CR) (45) were chosen for their structural diversity. Full-length 2N4R tau was incubated
with ARA and varying concentrations of Hsp70 for 18 hours and the resulting amount of
aggregation was assayed by laser light scattering (LLS) (Figure 1A), thioflavin S (ThS)
(Figure 1B) and transmission electron microscopy (TEM) (Figure 1C-E). The data was
background corrected using reactions that were similar to each concentration of Hsp70, but
lacked tau (Supplemental Figure 1). At low concentrations of Hsp70, there was little
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observable effect. However, increasing the concentration of Hsp70 reduced the amount of
tau aggregation observed. Maximal inhibition was observed at a 2:1 molar ratio of tau to
Hsp70. The higher concentrations of Hsp70 causing a decrease in overall tau aggregation
also caused a noticeable decrease in aggregate lengths (Figure 1D, E) in comparison to
controls lacking Hsp70 (Figure 1C).
Hsp70 was also added to CR induced tau aggregation reactions at varying concentrations
and analyzed by LLS (Figure 2A) and TEM (Figure 2B-D). The data was background
corrected using reactions that were similar to each concentration of Hsp70, but lacked tau
(Supplemental Figure 2). The amount of tau aggregation detected by LLS decreased
significantly with increasing concentrations of Hsp70 (Figure 2A). Additionally, a decrease
in aggregate lengths and an increase in the number of aggregates observed per field was seen
with increasing Hsp70 concentrations (Figure 2C, D) as compared to reactions without
Hsp70 (Figure 2B). Hsp70 was also added to heparin sulfate induced tau aggregation
reactions and analyzed by ThS (Figure 3A) and TEM (Figure 3B-D). Similar to the ARA
and CR, the data was background corrected using reactions that were similar to each
concentration of Hsp70, but lacked tau (Supplemental Figure 3). Again, increasing the
concentration of Hsp70 dramatically decreased the amount of tau aggregation (Figure 3A).
Visualization of samples by TEM without Hsp70 revealed only very long aggregates (Figure
3B). These aggregates were so long that the ends did not fit into a 6 μm by 6 μm field of
view. Upon addition of Hsp70, aggregate lengths decreased and the number of aggregates
observed per field increased (Figure 3C, D). Electron micrographs of each Hsp70
concentration showed with increasing concentrations of Hsp70, the aggregate lengths began
to shorten (Supplemental Figure 4). Together, these data indicate that Hsp70 decreases tau
aggregation independent of the inducer employed despite the fact that these compounds
(ARA, CR and heparin) are structurally distinct.
Hsp70 can act in an ATP independent manner to inhibit tau aggregation
Hsp70 normally functions by hydrolyzing ATP to ADP in the ATPase domain to enhance
the association with a ligand. We therefore sought to determine whether the addition of ATP
would affect Hsp70 inhibition of tau aggregation. As expected, the addition of ATP and a
non-hydrolyzable analog ATPγS reduced the Hsp70 inhibition of tau aggregation at two
different tau concentrations (Figure 4A-D). The presence of ATP reduces the affinity of
Hsp70 for its client proteins and the lack of co-chaperones or nucleotide exchange factors
greatly reduces the ATPase activity and cycling to the higher affinity ADP + phosphate
state. The similarity between ATP and the non-hydrolyzable analog ATPγS strongly
suggests that this is the case. We therefore sought to determine whether the ATP inhibition
of Hsp70 could be overcome by increasing the concentration of Hsp70 with respect to tau.
Increasing the concentration of Hsp70 to 1 μM in the presence of 2 μM tau greatly reduced
the effect of ATP on the inhibition of tau aggregation (Figure 4E-F).
The occasional disagreement between ThS and LLS results (compare Figure 4C with Figure
4D) can indicate a difference in filament morphologies. We therefore examined the
aggregation morphologies by electron microscopy. We found that the addition of ATP to tau
in the absence of Hsp70 (Figure 5C, D) increased the frequency of smaller aggregates as
compared to tau alone (Figure 5A, B), despite similar levels of overall aggregation as
determined by ThS fluorescence. We also observed that tau incubated with Hsp70 (Figure
5E, F) or Hsp70 and ATP (Figure 5 G, H) had similar aggregate frequency distributions,
despite being significantly different by ThS fluorescence measurements. Finally, we
observed that the addition of ATPγS and Hsp70 (Figure 5I, J) had fewer aggregates overall,
as indicated by the lower amplitude frequency distribution of small aggregates when
compared to tau aggregated with Hsp70 (Figure 5E,F) or Hsp70 and ATP (Figure 5G, H).
While it is clear that nucleotide addition is having an effect on Hsp70 inhibition of tau
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aggregation, it should be noted that in the future similar experiments with co-chaperones and
nucleotide exchange factors will be required for a full understanding of the role of
nucleotides in this process.
Hsp70has modest effects on pre-formed tau aggregates
We have shown that Hsp70 can prevent aggregation of tau when added at the beginning of
the reaction. While Hsp70 is not known to break apart aggregates of protein, it could
potentially aid in this process by removing tau from the ends of pre-formed aggregates. We
therefore added Hsp70 to preformed tau aggregates and assessed changes in filament
morphologies. 2N4R tau was aggregated in the presence of ARA for 6 hrs. Either buffer
alone (Figure 6A, B), 1 μM Hsp70 alone (Figure 6C, D), or 1 μM Hsp70 and 2 mM ATP
(Figure 6E, F) was added to separate reactions, incubated for an additional 12 hrs, and
visualized by TEM. The lengths of the individual aggregates were determined, converted to
log scale and summarized as a frequency distribution. The addition of Hsp70 to pre-formed
aggregates resulted in a reduction of longer aggregates and an increase in the frequency of
smaller aggregates (compare the dashed fit of 2N4R tau alone to the solid fit of 2N4R tau +
Hsp70, Figure 6D). The combination of Hsp70 and ATP added to pre-formed aggregates
resulted in a further reduction in longer aggregates and a concomitant increase in shorter
aggregates (Figure 6E, F), suggesting the possibility that nucleotides could play a role in the
Hsp70 disassembly of pre-formed tau filaments. These results are consistent with previous
results that Hsp70 has only modest effects on pre-formed tau filaments (30).
Hsp70 differentially inhibits aggregation of individual tau isoforms
Tau exists as six alternatively spliced isoforms that differ in primary sequence, with 2
alternatively spiced exons in the amino terminal region of tau and another alternatively
spliced exon near the carboxy terminus (Figure 7A). The absence of MTBR2 in 3R isoforms
causes a decrease in microtubule binding ability and overall aggregation potential in the
presence of ARA as compared to 4R isoforms (17, 39, 40, 52). We therefore sought to
determine whether Hsp70 would have disparate effects on the aggregation of the tau
isoforms. The six individual tau isoforms (4 μM) were induced to aggregate using ARA in
the presence of varying concentrations of Hsp70. The extent of aggregation was determined
using LLS (Figure 7B) and ThS (Figure 7C). Hsp70 inhibited ARA-induced aggregation of
each tau isoform in a dose-dependent manner, but the inhibition curves were different. In the
presence of low Hsp70 concentrations (less than 0.25 μM Hsp70) there was a dramatic
decrease in aggregation for 3R isoforms while 4R isoforms were largely unaffected at this
concentration. 3R isoforms were almost maximally inhibited at higher Hsp70 concentrations
that only inhibited 4R isoforms by approximately 50%. 3R tau containing both N-terminal
inserts (2N3R) was inhibited at lower concentrations of Hsp70 as compared to 0N3R and
1N3R. In comparison, Hsp70 affected all three 4R isoforms similarly. The IC50 for each tau
isoform is reported in Table 1.
Inhibition of the aggregation of different tau isoforms was confirmed using TEM (Figure 8).
Hsp70 was used at a concentration corresponding to half maximal and maximal inhibition
levels. In general, the addition of Hsp70 resulted in a decrease in the number of longer
aggregates and a concomitant increase in the number of shorter aggregates as indicated by
an increase in amplitude and shift in maxima to the left with the addition of Hsp70 (Figures
8C, F, I, L, O, R). The 3R isoforms were inhibited at lower concentrations of Hsp70 than
what was observed for 4R isoforms. There were subtle differences in the patterns of
inhibition, but these seem small in comparison to the effect of the extra MTBR, suggesting
the likelihood that the N-terminal repeats do not play a large role in modulating Hsp70
interactions with tau. The frequency distributions for the 0N4R isoform are more difficult to
interpret due to aggregates clumping in the absence of Hsp70 (Supplemental Figure 5). The
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results for all the tau isoforms indicate that there is a general inhibition of aggregate
elongation and are consistent with Hsp70 differentially affecting the tau isoforms.
Hsp70 has modest effects on tau-stimulated microtubule assembly
Tau is a microtubule associated protein and previous work has shown that Hsp70 increases
the affinity of tau for microtubules in cultured cells (23). We therefore sought to determine
whether Hsp70 influences tau-stimulated microtubule assembly by incubating each tau
isoform with and without Hsp70 in the presence of tubulin (Figure 9). The ratio of tau to
Hsp70 employed (1:1 ratio) was enough to achieve maximal inhibition of tau aggregation in
vitro (see Figure 7). The lag time, maximum amount and rate of microtubule assembly were
determined for each isoform in the presence and absence of Hsp70 by fitting the data to a
growth curve. The buffer only and Hsp70 only in the absence of tau both show no
stimulation of microtubule assembly (Figure 9F). Each isoform robustly stimulated
microtubule assembly in the presence and absence of Hsp70 (Figure 9A-F), although some
significant differences in the presence of Hsp70 were observed (Table 2). Two isoforms had
changes in the maximum amount of tubulin assembly (2N3R, 0N4R), two isoforms were
significantly altered in all three kinetic parameters (0N3R, 1N4R) and two isoforms were
not significantly affected by Hsp70 (2N4R, 1N3R). However, the changes observed seemed
minor in comparison to the degree of inhibition of tau isoform aggregation caused by Hsp70
(see Figures 7 and 8).
DISCUSSION
Expression of Hsp70 is elevated in AD, possibly in response to oxidation and inflammatory
events (63-67). The inverse relationship of Hsp70 expression and tau pathology in
hippocampal neurons suggests that the up-regulation of Hsp70 is protective against
abnormal and aggregated tau. Previous studies demonstrated that higher levels of Hsp70 in
cultured cells can decrease the levels of insoluble 0N3R or 2N4R tau and increase their
association with microtubules (23). Due to these and other observations of interactions
between tau, Hsp70 or Hsp70 family members (23-27), we sought to determine whether
Hsp70 was a general inhibitor of tau aggregation in vitro. The aggregation of 2N4R tau
induced by any of three different compounds (ARA, CR or heparin) was significantly
inhibited in the presence of Hsp70. The ability of Hsp70 to reduce the aggregation induced
by such structurally distinct molecules strongly suggests that Hsp70 inhibition is not inducer
specific, but rather specific to tau, bolstering its potential as a neuronal inhibitor of tau
aggregation. While a strong argument can be made for a biological role for ARA in the
induction of tau aggregation in AD (68), it is currently unknown whether in vivo tau
aggregation requires an inducer or what the nature of that inducer may be. We have
demonstrated that Hsp70 can inhibit tau aggregation triggered by a wide variety of inducer
molecules, suggesting that Hsp70 is a general inhibitor of tau aggregation, perhaps capable
of blocking most tau inducers or aggregation in the absence of inducers.
Although Hsp70 is highly effective at preventing the aggregation of 2N4R tau in vitro (30),
very little was known about its effect on the other isoforms of tau that arise from alternative
splicing. Several factors suggest that the interaction between Hsp70 and tau isoforms may
not be the same. First, one of the putative Hsp70-binding sites is believed to be located
adjacent to the second MTBR, a region absent in 3R isoforms (26). Secondly, tau is believed
to adopt a global hairpin conformation in solution in which the amino terminus folds over to
come in close proximity to the carboxy terminal tail and the MTBRs (69). Exons 2 and 3
reside near the N-terminus and the presence or absence of these exons may influence the
folding of this region and, thus, the formation of the hairpin conformation. We therefore
sought to determine whether Hsp70 would differentially influence the aggregation of tau
isoforms. To this end, we demonstrated that Hsp70 was more effective in inhibiting the
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aggregation of 3R isoforms and that the N-terminal exon 3 had only a small effect in the 3R
isoforms and none in the 4R isoforms.
One potential mechanism that would explain the increased inhibition of 3R isoforms as
compared to 4R isoforms can be deduced from the inhibition data. If we assume that the
decrease in polymerization is directly proportional to the amount of bound Hsp70, we can
treat the inhibition curves as binding isotherms (Figure 10). Unfortunately, the 3R and 4R
inhibition curves cannot be adequately approximated by a single binding equation. However,
previous results have shown that a constitutively expressed heat shock protein, Hsc70,
which shares approximately 90% sequence identity with Hsp70, can bind to tau isoforms at
two separate sites (275VQIINK280 and 306VQIVYK311, hexapeptide motifs located in exon
10 and near MTBR3, respectively). We therefore used a single-site model to fit 3R
inhibition and a 2-site model to fit 4R inhibition. The fit of the data was greatly improved by
assuming that Hsp70 is binding to an oligomer (i.e. max binding is less than 1), which is
consistent with our previously published report (30). The 4R data was better fit to the 2-site
binding equation assuming that the second site is lower affinity than the first and that only
tau molecules that are doubly occupied are inhibited (Figure 10). The following inferences
can therefore be drawn from fitting the data to these equations: a) It is likely that the site of
Hsp70 inhibition is at the end of the aggregate, preventing the addition of new tau molecules
onto the growing end; b) binding could occur before or after addition to the growing
aggregate, but it is the act of blocking the next oncoming tau to the end that results in
inhibition; and c) 4R tau with a single Hsp70 bound could still use its second unbound
aggregation site to participate in the aggregation process and allow another tau molecule to
add to the end.
While results indicate that the inhibition of tau aggregation can occur without hydrolysis of
ATP, we cannot fully address the role of ATP hydrolysis in Hsp70 inhibition of tau
aggregation in the current study. It seems likely that Hsp70 is not cycling through ATP
hydrolysis and exchange due to the lack of co-chaperones and nucleotide exchange factors.
The similarity in results between ATP and ATPγS also indicates that ATP cycling is not
required for Hsp70 inhibition of tau aggregation. It is likely that the co-chaperones such as
Hsp40 and nucleotide exchange factors such as BAG-1 will have a large impact on the
function of Hsp70 and its regulation of tau aggregation. It is also just as likely that other
chaperones with similar functions to Hsp70 could also inhibit tau aggregation. Our current
study provides a benchmark for future analyses of chaperone/co-chaperone inhibition of tau
aggregation. It is potentially significant that Hsp70 is capable of protecting tau from
aggregation without the need for ATP hydrolysis and cycling given the high degree of
mitochondrial dysfunction and altered metabolism present in the brains of Alzheimer's
patients (70). The observation that Hsp70 can serve a protective role even in suboptimal
energetic conditions is encouraging as one considers potential therapeutic applications.
The predicted sites of Hsp70 binding are located with the MTBR region, thereby raising the
possibility that Hsp70 binding to this region could inhibit the normal functions of tau
through steric hindrance. Previously, it was demonstrated that increased Hsp70 expression
levels in cultured cells resulted in the increased association of tau with microtubules. This
indicates Hsp70 does not interfere with the ability of tau to associate with microtubules.
However, phosphorylation of tau can significantly decrease its stabilization of microtubules
while maintaining substantial interactions with preformed microtubules (71). We therefore
sought to determine whether Hsp70 would affect the microtubule nucleation and
stabilization properties of tau isoforms. Even in the presence of equimolar concentrations of
Hsp70, tau isoforms robustly assembled microtubules. However, Hsp70 did significantly
affect the amount of time required to begin to polymerize tubulin (lag time), depressing both
the rate of microtubule assembly and the steady state levels of microtubule assembly in the
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presence of 0N3R and 1N4R tau. 0N4R and 2N3R also had significantly reduced levels of
microtubule assembly, while 1N3R and 2N4R were unaffected by Hsp70. There does not
appear to be a consistent pattern of exon incorporation that correlates with the effects of
Hsp70 on tau function. This could indicate that the interaction of Hsp70 with tau isoforms is
complicated by their different conformational states. However, it should be noted that the
largest changes observed, though significant, represent only a 29% increase in microtubule
assembly rate and a 30% decrease in microtubule lag time in the presence of 1N4R.
Therefore, while our data demonstrate that Hsp70 acts specifically on certain isoforms to
change their ability to associate with microtubules, all maintain their ability to stabilize
microtubules and the observed changes are small in comparison to the observed effects of
Hsp70 inhibition of tau aggregation.
In conclusion, we demonstrated that Hsp70 inhibited the aggregation of tau in an isoform-
specific fashion, but allowed for robust microtubule assembly. These data, in conjunction
with previous studies, indicate that increased Hsp70 levels can inhibit the dysfunction of tau
(aggregation) while allowing the normal microtubule assembly and binding function of tau
to remain intact, confirming up-regulation of Hsp70 levels/activity as an attractive potential
therapeutic for neurodegenerative tauopathies. Additionally, the differences in Hsp70
interactions with tau isoforms, especially 3R vs. 4R, stresses the importance of considering
the nature of tau isoforms used in modeling tau neurodegeneration both in vitro and in vivo.
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Figure 1. Hsp70 inhibition of arachidonic acid (ARA) induced 2N4R tau aggregation
4 μM 2N4R tau and 150 μM ARA was incubated in the presence of varying amounts of
Hsp70 (0-2 μM) for 18 hrs at 37 °C. Aggregation was measured by (A) LLS and (B) ThS
fluorescence. Data is in arbitrary units and represents the average equilibrium amounts
obtained from 3 trials ± SD with controls for the same reaction without tau subtracted as
background for each data point (see Supplemental Figure 1). Representative TEM images
are shown for aggregation reactions at (C) 0 μM (no inhibition), (D) 0.5 μM (half maximal
inhibition) and (E) 1 μM Hsp70 (maximal inhibition). The scale bar represents 500 nm.
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Figure 2. Hsp70 inhibition of Congo red (CR) induced 2N4R tau aggregation
2 μM 2N4R tau and 10 μM CR was incubated in the presence of varying amounts of Hsp70
(0-2 μM) for 18 hrs at 37 °C. Polymerization was measured by (A) LLS. Data is in arbitrary
units and represents the average of 3 trials ± SD with controls for the same reaction without
tau subtracted as background for each data point (see Supplemental Figure 2). ThS
fluorescence could not be used as in Fig. 1 due to CR interference. Representative TEM
images are shown for aggregation reactions at (B) 0 μM (no inhibition), (C) 0.5 μM (half
maximal inhibition), and (D) 1 μM Hsp70 (maximal inhibition). The scale bar represents
500 nm.
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Figure 3. Hsp70 inhibition of heparin induced 2N4R tau aggregation
2 μM 2N4R tau and 6 μg/ml heparin was incubated in the presence of varying amounts of
Hsp70 (0-2 μM) for 18 hrs at 37 °C. Aggregation was measured by (A) ThS fluorescence.
Data is in arbitrary units and represents the average of 3 trials ± SD with controls for the
same reaction without tau subtracted as background for each data point (see Supplemental
Figure 3). LLS was not measured as in Figures 1 and 2 due to the very low levels of light
scattering that exist with heparin induced aggregation (see Supplemental Figure 3).
Representative TEM images are shown for (B) 0 μM (no inhibition), (C) 0.5 μM (half
maximal inhibition), and (D) 1 μM Hsp70 (maximal inhibition). The scale bar represents
500 nm.
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Figure 4. ATP reduces the effect of Hsp70 on tau aggregation
Aggregation of 4 μM 2N4R tau alone, or in the presence of 1 μM Hsp70, 1 μM Hsp70 + 500
μM ATP, or 1 μM Hsp70 + 500 μM ATPγS was measured by ThS fluorescence (A) and
LLS (B). Aggregation of 2 μM 2N4R tau alone, or in the presence of 0.5 μM Hsp70, 0.5 μM
Hsp70 + 500 μM ATP, or 0.5 μM Hsp70 + 500 μM ATPγS was measured by ThS
fluorescence (C) and LLS (D). Aggregation of 2 μM 2N4R tau alone, or in the presence of 1
μM Hsp70, 1 μM Hsp70 + 500 μM ATP, or 1 μM Hsp70 + 500 μM ATPγS was measured
by ThS fluorescence (E) and LLS (F). Significant differences (ns = p > 0.05, * = 0.01 < p <
0.05, ** = 0.001 < p < 0.01, and *** = p < 0.001) are denoted with asterisks. Data is in
arbitrary units and represent the average of 3 trials ± SD.
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Figure 5. TEM analysis of ATP and Hsp70 effects on tau aggregation
Representative electron micrographs (left) and the transformed aggregate lengths (right)
from reactions containing (A, B) 2N4R tau alone, (C, D) 2N4R tau with 500 μM ATP, (E, F)
2N4R tau with 1 μM Hsp70, (G, H) 2N4R tau with 1 μM Hsp70 + 500 μM ATP, and (I, J)
2N4R tau with 1 μM Hsp70 + 500 μM ATPγS. The data is the distribution of five fields per
reaction and plotted as the number of aggregates per field versus the log(bin center) and is
fit to a Gaussian equation. The scale bar represents 500 nm.
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Figure 6. ATP enhances Hsp70 disassembly of pre-formed tau aggregates
4 μM 2N4R tau was induced to aggregate with 150 μM for 6 hrs at 37 °C. Following
incubation no additional components (A, B), 1 μM Hsp70 (C, D), or 1 μM Hsp70 with 2
mM ATP (E, F) was added to the reaction for an additional 12 hrs at 37 °C. Reactions were
visualized by TEM (A, C, E) and quantitated using Image Pro Plus. The data was
transformed to the log scale and the frequency distribution of five fields per reaction was
plotted as a function of number of aggregates per field versus the log(bin center) (B, D, F)
and fit to a Gaussian equation. The scale bar represents 500 nm. The dashed line in (D) and
(F) is the Gaussian fit of 2N4R alone.
Voss et al. Page 20













Figure 7. Hsp70 inhibition of ARA induced tau isoform tau aggregation
(A) Schematic of the six tau isoforms used in this study. 4 μM tau isoforms and 150 μM
ARA were incubated in the presence of varying amounts of Hsp70 (0-2 μM) for 18 hrs at 37
°C. Aggregation was measured by (A) LLS and (B) ThS fluorescence, with controls for the
same reaction without tau subtracted as background for each data point. LLS and ThS values
were normalized to the largest observed value as 100% and the lowest observed value as 0%
and plotted against the log([Hsp70]). Each data point represents the average of 3 trials ± SD.
Isoforms are identified by the symbols as indicated in the key of the graphs.
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Figure 8. Electron micrographs of Hsp70 inhibited tau isoform aggregation with ARA
Upper panel: representative images are shown for 3R isoforms without Hsp70 (left column,
A, D and G), and with Hsp70 at a maximal inhibition concentration (0.5 μM) (right column,
B, E and H). Lower panel: representative images are shown for 4R isoforms without Hsp70
(left column, J, M and P), and with Hsp70 at a maximal inhibition concentration (1 μM)
(right column, K, N and Q). Scale bars represent 1 μm. Electron micrographs of aggregation
reactions performed at three different Hsp70 concentrations corresponding to no inhibition
(closed circles), half maximal inhibition (open squares) and maximal inhibition (open
circles) were analyzed for aggregate length. Aggregate lengths were transformed to the log
scale and binned at an interval of 0.1 nm centers, plotted as the mean of the number of
aggregates in a given bin per field ± SD (symbols) of 5 fields and fit to a Gaussian
distribution (lines). Graphs for the six isoforms are individually labeled (C – 0N3R; F –
1N3R; I – 2N3R; L – 0N4R; O – 1N4R; and R – 2N4R). The shift in distribution of
aggregates towards longer lengths for the 0N4R isoform (L) at the Hsp70 IC50 (half
maximal inhibition) concentrations was due to aggregate clumping (see Supplemental
Figure 5).
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Figure 9. Microtubule assembly with tau isoforms and Hsp70
1 μM tau isoforms were incubated with 1 μM tubulin in the presence (○) or absence (●) of 1
μM Hsp70 at 37 °C. Fluorescent readings at 355 nm excitation and 460 nm emission were
taken every minute for 1 hr. Graphs for the six isoforms are individually labeled. Data
shown is every other minute for ease of viewing and is plotted as the mean ± SD of 3 trials.
Control reactions for tubulin with 1 μM Hsp70 (◇) or tubulin with buffer alone (▲) are
shown in (F). The straight dashed line in each graph indicates 0 RFU.
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Figure 10. Hsp70 binding models
Hsp70 inhibition of 3R and 4R isoforms are redrawn from Figure 7B and overlaid with
simulated data using a 1 site binding equation (dashed black line) and a 2 site binding
equation (solid black line). Details for obtaining the fits to the data are provided in Materials
and Methods.
Voss et al. Page 24

























Voss et al. Page 25
Table 1
IC50 values for Hsp70 inhibition of tau isoforms ARA induction of polymerization
IC50 Hsp70, μM
ThS LLS
0N3R 0.20 ± 0.03 0.16 ± 0.02
1N3R 0.15 ± 0.01 0.14 ± 0.01
2N3R 0.09 ± 0.01 0.09 ± 0.01
0N4R 0.67 ± 0.07 0.26 ± 0.04
1N4R 0.57 ± 0.04 0.64 ± 0.16
2N4R 0.56 ± 0.05 0.55 ± 0.04
Concentration of Hsp70 (in μM) required to inhibit the maximum ARA-induced tau isoform polymerization by 50% (IC50) was determined by
fitting ThS and LLS data to a normalized inhibitory dose-response variable slope curve. Data given is the mean ± SD of 3 trials.
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Table 2
Statistics of microtubule assembly with tau isoforms and Hsp70.
Hsp70 Ymax (RFU) Kapp (min-1) Lag (min)
0N3R - 0.88 ± 0.01 0.24 ± 0.01 3.72 ± 0.03
+ 0.72 ± 0.01* 0.19 ± 0.00* 3.27 ± 0.05*
1N3R - 0.82 ± 0.01 0.20 ± 0.00 6.18 ± 0.42
+ 0.79 ± 0.00 0.19 ± 0.00 6.76 ± 0.06
2N3R - 0.83 ± 0.01 0.15 ± 0.01 4.25 ± 0.41
+ 0.72 ± 0.02* 0.14 ± 0.01 4.66 ± 0.37
0N4R - 0.82 ± 0.02 0.19 ± 0.01 3.58 ± 0.22
+ 0.72 ± 0.01* 0.19 ± 0.01 3.19 ± 0.13
1N4R - 0.82 ± 0.01 0.14 ± 0.00 6.05 ± 0.13
+ 0.77 ± 0.01* 0.18 ± 0.01* 4.21 ± 0.30*
2N4R - 0.79 ± 0.10 0.13 ± 0.01 6.19 ± 0.34
+ 0.82 ± 0.00 0.15 ± 0.00 5.59 ± 0.14
Microtubule polymerization data were fit to the Gompertz growth curve to analyze the lag time, kapp (proportional to rate), and maximum
polymerization. Data are the average of 3 independent trials ± SD. The asterisk denotes statistical significance at p<0.05.
Biochemistry. Author manuscript; available in PMC 2013 January 31.
